http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3999662-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bda5416e591d3d33059f20c4f65f9c90 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2019-07-19^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e4dd8538fd1f661adcb572b5099250 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7a7798502024953d0db57a8a809732c |
publicationDate | 2022-05-25^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3999662-A1 |
titleOfInvention | Characterization of prostate cancer using dna methylation assay system |
abstract | The present invention (PROMESYS) relates to methods and tools for diagnosis and prognosis of prostate cancer, patient monitoring/follow-up and prediction of response to treatment of patients with confirmed diagnosis of prostate cancer. The methods conducted in vitro comprise the steps of providing a tissue and/or a body fluid sample, obtained from an individual, and determining DNA methylation status and/or level of one or more genes selected from the group consisting of PRKCB, ADAMTS12, NAALAD2, FILIP1L, ZMIZ1 and KCTD8 in a sample. Additionally, methylation status and/or level of CCDC181, MT1E, APC and/or RASSF1 can be included in the biomarker panel for improved performance. Furthermore, the present invention refers to kits and oligonucleotides for use in such a method. |
priorityDate | 2019-07-19^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 131 of 131.